ISSN: 1859 - 2872
Evaluating treatment results of gefitinib as a first-line therapy in patients with advanced stage non-small cell lung cancer harboring sensitve EGFR mutations
Main Article Content
Keywords
Abstract
Objective: To assess the overall response rate (ORR), the progressive-free survival (PFS) and the overall survival (OS) for the first-line gefitinib in EGFR-mutated advanced NSCLC patients and common side effects. Subject and method: 58 NSCLC patients, adenocarcinoma type, EGFR positive, stage IIIB/IIIC/IV were treated with first-line Gefitinib from July 2015 to July 2020 at Bach Mai hospital. Restrospective study. Result: PFS and OS of the subgroups were recorded to assess the response to the target treatment. Results showed that ORR is 75.9%, median PFS and OS are 12.5 months and 21.5 months, respectively. Common side effects are skin rash with rate of 65.5%; most cases were at grade 1 or 2. Conclution: First-line gefitinib has good treatment effectiveness and can prolong the survival of the advanced NSCLC patients haboring sensitive EGFR mutations. Side effects are negligible.
Article Details
References
2. Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE (2013) Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5): 341-368.
3. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25): 2380-2388.
4. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10): 947-957.
5. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2): 121-128.
6. Nguyễn Bá Đức, Bùi Công Cường, Trần Văn Thuấn (2007) Chẩn đoán và điều trị bệnh ung thư. Ung thư phổi, tr. 176-187.
7. Shi Y, Au JS, Thongprasert S, Srinivasan S et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2): 154-162.
8. Nguyễn Minh Hà, Trần Huy Thịnh, Trần Vân Khánh và cộng sự (2014) Erlotinib bước 1 trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn có đột biến EGFR. Tạp chí Nghiên cứu Y học, phụ chương 91(5), tr. 6-12.
9. Đỗ Mai Linh, Lê Văn Quảng (2017) Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ bằng thuốc ức chế Tyrosine Kinase. chương 3, tr. 33-53.
10. Lê Thu Hà, Trần Văn Thuấn (2016) Đáp ứng thuốc Erlotinib trong điều trị bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn. Y học thực hành, 993, tr. 53-55.
Article Sidebar
